IMNN Imunon: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
The prospects for Imunon, Inc. (IMNN) are driven by plasmid therapy trials for ovarian cancer, with the market having already priced in development costs. The EV/EBITDA market trend, which stands at 0.00, underscores that business sustainability depends on drug approvals given the absence of regular profits. Simultaneously, Imunon, Inc. (IMNN) is implementing ESG principles by minimizing harmful laboratory emissions and maintaining strict ethical compliance.
imunon.com - analytical breakdowns and key metrics (IMNN)
- market price and analyst price targets:
- company stock capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
- net income and valuation multiples indicators:
IMNN - Net Income|Expected Profit Imunon, Inc.|IMNN - Price to Earnings Multiple|Future Price to Earnings Imunon|IMNN - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple IMNN|IMNN - Operating profit before amortization|Earnings per share for the last twelve months Imunon|IMNN - Earnings per share for the last 12 months|Quarterly EPS earnings growth imunon.com|IMNN - Earnings growth in current year|Earnings growth forecast for next year Imunon, Inc.
Analysis of all company metrics:Celsion Corporation (IMNN)
This multiple compares the total enterprise value, including net debt, to its operating income before taxes and amortization, allowing for the determination of the business's real value regardless of the financing structure. By analyzing the EV/EBITDA ratio, accounting for debt and amortization, for Imunon, Inc. (IMNN), an investor assesses the company's capitalization against management's expenditures on DNA immunotherapy development, which is critical for determining the efficiency of investments in clinical phases.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization tempus.com TEM|Qiagen Corp (QGEN) - Company Value to EBITDA|IONS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|RGEN (repligen.com) - Enterprise Value to Operating Income Before Depreciation|RNA (Avidity Biosciences, Inc.) - Enterprise Value to EBITDA Ratio|CRISPR Therapeutics Inc - Business Value to Operating Income Before Depreciation|WGS (Sema4) - EV/EBITDA Multiple|Ultragenyx Corp (RARE) - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Beam Therapeutics Inc. (BEAM)|sarepta.com - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple TWST (Twist Bioscience, Inc.)|TXG - Enterprise Value to EBITDA Ratio|NTLA: Enterprise Value to EBITDA Ratio|Total Company Value to Operating Income Before Depreciation Ratio Stoke Corp STOK|BLFS: EV/EBITDA Multiple|WVE - Total Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Maze Therapeutics|Enterprise Value to EBITDA Ratio Sionna Therapeutics, Inc. (SION)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Prime Medicine Corp (PRME)|Taysha Corp - Enterprise Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization uniQure N.V. QURE|MGTX: Enterprise Value to Operating Income Before Depreciation|REGENXBIO - EV/EBITDA Multiple|SLDB (Solid Biosciences Inc) - Enterprise Value to Operating Income Before Depreciation|Ocugen Corp (OCGN) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation PACB|BNTC (Benitec Biopharma Inc.) - EV/EBITDA Multiple|EV/EBITDA Multiple designtx.com|EV/EBITDA Multiple RCKT|Total Company Value to Operating Income Before Depreciation Ratio 4DMT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Lexeo Therapeutics, Inc. LXEO|KRRO - Enterprise Value to EBITDA Ratio|EDIT: Enterprise Value to EBITDA Ratio|SLN - EV/EBITDA Multiple|proqr.com (PRQR) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation CDXS|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sangamo|Company Value to EBITDA Nautilus Biotechnology Inc NAUT|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Metagenomi, Inc. (MGX)|precisionbiosciences.com - Enterprise Value to Operating Income Before Depreciation|Generation Bio - Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation BOLD|Exicure Corp - EV/EBITDA Multiple|Total Company Value to Operating Income Before Depreciation Ratio Phio Pharmaceuticals PHIO|mustangbio.com (MBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano Genomics Inc.) - EV/EBITDA Multiple|Enterprise Value to EBITDA Ratio Applied DNA Sciences Inc (APDN)|Enterprise Value to EBITDA Ratio BLUE (Bluebird Bio)|Total Company Value to Operating Income Before Depreciation Ratio immunoprecise.com|EV/EBITDA Multiple OMGA (Omega Therapeutics)|Total Company Value to Operating Income Before Depreciation Ratio singulargenomics.com (OMIC)|RGLS - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Syros Pharmaceuticals Inc. (SYRS) - Enterprise Value to EBITDA Ratio|Codex DNA (TBIO) - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Enterprise Value to Operating Income Before Depreciation TCON|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology
